Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)

NCT06939036 is registered in ClinicalTrials.gov with Ariceum Therapeutics GmbH as lead sponsor.

NCT NCT06939036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06939036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)
Lead sponsor
Ariceum Therapeutics GmbH
Phase
Phase 1/2
Overall status
Terminated
Start date
July 1, 2025
Completion date
December 31, 2025
Enrollment
2 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

merkel cell carcinoma, small cell lung cancer extensive stage